FDA Expands Warning Labels on COVID Vaccines for Young Males

The U.S. Food and Drug Administration has announced a revision to the warning labels on COVID-19 vaccines from Pfizer and Moderna. The change comes in response to rare cases of myocarditis—heart inflammation—linked to the vaccines in young males.

Previously, Moderna’s label warned of myocarditis risk in males aged 18 to 24, while Pfizer’s warning focused on boys aged 12 to 17. Moving forward, both companies will update their warning labels to include males between the ages of 16 and 25.

Myocarditis remains an extremely rare side effect. The condition has been observed in approximately 38 males per million doses administered. According to health officials, most cases resolve quickly and with minimal treatment.

This labeling update is the latest in a series of changes surrounding COVID-19 vaccination guidance. Earlier this year, the FDA announced that beginning this fall, the vaccine will be offered only to people aged 65 and older or those with underlying health conditions.

The updated guidelines reflect a shift in national strategy as COVID-19 moves into an endemic phase and vaccination efforts become more targeted.

Credit: NBC Palm Springs

Explore: NBCPalmSprings.com, where we are connecting the Valley.